Dr. G. Yancey Gillespie obtained B.A. (Biology & Chemistry), M.Sc. (Cytogenetics) and Ph.D. (Immunology & Immunogenetics) degrees at the University of Mississippi, finishing in 1971. Following a NCI F32 postdoctoral fellowship at the  Kansas University Medical Center, he was appointed to the Department of Pathology as Instructor. In 1975, he joined Scripps Clinic and Research Foundation in La Jolla. In 1977, he moved as Assistant Professor of Pathology to the University of North Carolina-Chapel Hill. In 1979, he transferred to the Department of Surgery, Division of Neurosurgery to direct the Brain Tumor Immunology research program. In 1986, Dr. Gillespie came to UAB as tenured Associate Professor of Surgery to direct brain tumor research efforts in the Division of Neurosurgery and to help establish the Neuro-Oncology Program in the Comprehensive Cancer Center. He is currently Professor of Neurosurgery with secondary appointments in the Departments of Microbiology and Cell, Developmental & Integrative Biology. Dr. Gillespie is Director of the UAB Brain Tumor Specialized Program Of Research Excellence (SPORE) and Co-Leader of the Neuro-Oncology Program in the Comprehensive Cancer Center. He directs both the Brain Tumor Tissue Core and the Brain Tumor Animal Models Core facilities.

Research Interests: Molecular and Viral Therapy of Malignant Primary Brain Tumors


Featured Publications:

Oliva CR, Moellering DR, Gillespie GY, Griguer CE. Acquisition of Chemoresistance in Gliomas Is Associated with Increased Mitochondrial Coupling and Decreased ROS Production. PLoS One. 2011;6(9):e24665. Epub 2011 Sep 9.

McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN. Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma. Mol Cancer Ther.;10(12):2384-93, 2011. PMID:  22027691 PMCID: PMC3237864

Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, Mehta T, McCubrey RO, Khodarev NN, Weichselbaum RR, Gillespie GY. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One. 2012;7(1):e29653. Epub 2012 Jan 5. PMID: 22242177 

Markert JM, Cody JJ, Parker JN, Coleman JM, Price KH, Kern ER, Quenelle DC, Lakeman AD, Schoeb TR, Palmer CA, Cartner SC, Gillespie GY, Whitley RJ.  Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012 May;86(9):5304-13. Epub 2012 Feb 29. PMID: 22379082

Jarboe JS, Anderson JC, Duarte CW, Mehta T, Nowsheen S, Hicks PH, Whitley AC, Rohrbach TD, McCubrey RO, Chiu S, Burleson TM, Bonner JA, Gillespie GY, Yang ES, Willey CD.  MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma. Clin Cancer Res. 2012 Jun 1;18(11):3030-41. Epub 2012 May 22. PMID: 22619307

Friedman GK, Haas MC, Kelly VM, Markert JM, Gillespie GY, Cassady KA. Hypoxia Moderates γ(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. Transl Oncol. 2012 Jun;5(3):200-7. Epub 2012 Jun 1. PMID: 22741039 

Friedman GK, Raborn J, Kelly VM, Cassady KA, Markert JM, Gillespie GY. Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Front Oncol. 2013;3:28. doi: 10.3389/fonc.2013.00028. Epub 2013 Feb 28. PMID:  23450706

Griguer CE, Cantor AB, Fathallah-Shaykh HM, Gillespie GY, Gordon AS, Markert JM, Radovanovic I, Clement-Schatlo V, Shannon CN, Oliva CR.  Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme.  PLoS One. 2013 Apr 10;8(4):e61035. doi: 10.1371/journal.pone.0061035. Print 2013.  PMID:  23593382